FDA user fee reauthorization linked to agency management changes by Rep. Barton.
This article was originally published in The Tan Sheet
Executive Summary
FDA USER FEE REAUTHORIZATION LINKED TO MANAGEMENT CHANGES BY REP. BARTON, which the House Commerce/Oversight Subcommittee chairman continues to view as a higher priority than reauthorization of user fees. During an April 23 Commerce/Health Subcommittee hearing on FDA, Rep. Joseph Barton (R-Tex.) maintained that his concerns may preclude his support of reauthorization of the Prescription Drug User Fee Act. "The record in my opinion doesn't justify continued authorization of PDUFA and unless we get some serious management reforms this summer, I probably will not support PDUFA reauthorization," Barton concluded.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning